News and Trends 4 Oct 2022 TrialSpark partners with Sanofi to acquire and develop clinical-stage novel therapies TrialSpark has announced a new partnership with global pharma company Sanofi to explore novel methods of bringing new treatments to patients faster and more efficiently. The collaboration will focus on jointly pursuing the acquisition/in-licensing and development of best-in-class, clinical-stage phase II and phase III drug candidates in areas of high unmet patient need. The partnership […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 ASPIRE set up to collaborate on amyloidosis A new group of biotech and pharma companies has been assembled by the Amyloidosis Research Consortium (ARC). ASPIRE (amyloidosis stakeholder partnerships for impact reach and equity), is a collaboration between biotech and pharmaceutical companies committed to advancing solutions, improving diagnosis and systems of care, and addressing obstacles to health equity on behalf of amyloidosis patients. […] October 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Aeglea BioTherapeutics updates homocystinuria program Aeglea BioTherapeutics, Inc. says dosing in the third cohort of the phase 1/2 clinical trial of pegtarviliase for the treatment of classical homocystinuria is under way. Patients in this cohort are receiving 1.35 mg/kg of pegtarviliase once weekly administered via subcutaneous injection; patients in cohorts 1 and 2 received doses of 0.15 mg/kg and 0.45 […] October 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Absolute Biotech launches as unified antibody company Absolute Biotech has launched as a unified company to join antibody-centric brands from around the world. Absolute Biotech specializes in antibody reagents and services, adding value to existing antibodies, reagents and kits through annotation, validation, sequencing, engineering and recombinant manufacturing. The combined company will leverage each brand’s antibody expertise to advance the creation and availability […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Spinoff Biohaven launches with $258M and “incredible pipeline” Biohaven Ltd. launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer in May 2022. The company, led by Vlad Coric as […] October 4, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Lumen Bioscience data show needle free spirulina-produced vaccination protects against malaria Lumen Bioscience has published data demonstrating a needle-free, spirulina-produced recombinant vaccine that protects against malaria. The research, conducted in collaboration with the University of Washington, was published in the peer-reviewed journal, Nature Partner Journals (NPJ) Vaccines. Lumen Bioscience pioneered genetic engineering methods to highly express bioactive proteins in spirulina. The published research details how this […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Ginkgo Bioworks acquires Altar and Circularis Ginkgo Bioworks has announced the acquisition of two biotech companies, Altar, a French firm with a proprietary adaptive evolution platform, and Circularis, which has a proprietary circular RNA and promoter screening platform. Altar acquisition A fleet of Altar’s automated adaptive laboratory evolution (ALE) instruments will be integrated into Ginkgo’s Foundry to serve customers across food and […] October 4, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 HumanFirst launches industry’s largest decentralized clinical trial database HumanFirst has launched two new versions of the Atlas platform designed specifically for researchers in industry (AtlasPro) and academia (AtlasEDU). Atlas was created by HumanFirst to unlock better research for all humans sooner, and has been used for planning and deployment of trustworthy hybrid and at-home clinical trials by 22 of the 25 largest pharmaceutical […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 FDA gives $1.3M grant to Biologics & Biosimilars Collective Intelligence Consortium The Biologics & Biosimilars Collective Intelligence Consortium (BBCIC) has received a major grant from the Food & Drug Administration (FDA) in support of biosimilars research. The award provides $1.3 million over two years for a new BBCIC study focused on increasing the efficiency of biosimilar drug development and review. The study, “Improving the Efficiency of […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Patents granted for Poolbeg Pharma influenza and respiratory virus infections treatments Poolbeg Pharma has been granted patents by the US Patent and Trademark Office (USPTO) for POLB 001, a small molecule immunomodulator for the treatment of severe influenza and POLB 002, a first-in-class, intranasally administered RNA-based immunotherapy for respiratory virus infections. POLB 001 The USPTO granted a patent for the majority of Poolbeg’s claims around the […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Discovery of how metastatic cancer cells infiltrate the liver may lead to new drugs Approximately 90% of cancer-related deaths are due to metastasis when cancer spreads and forms new tumors. The liver is considered the most vulnerable organ to metastatic cancer: the five-year survival rate after surgery to remove liver metastases is as low as 30 to 50%, so developing treatments to prevent liver metastasis is urgently needed. A […] October 4, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Astellas and Pantherna to work together on mRNA-based medicine through direct reprogramming Astellas Pharma Inc. and Pantherna Therapeutics GmbH have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation). Direct reprogramming is the direct conversion of the fate of cells without passing through the pluripotent state. This agreement expands the scope of the technology evaluation agreement for […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email